BUCHANG PHARMA(SH:603858) Jin Rong Jie·2026-01-13 03:35Group 1 - The core viewpoint of the news is that Tonghua Guhong Pharmaceutical Co., Ltd. has received significant recognition in technological innovation and green development, including re-certification as a national high-tech enterprise and selection as a typical case for the "Beautiful Factory" initiative in Jilin Province [1][3][6] Group 2 - Tonghua Guhong Pharmaceutical has successfully passed the national high-tech enterprise re-certification for the fourth consecutive time since 2013, which evaluates the company's technological innovation capabilities and achievement transformation levels [3] - As a wholly-owned subsidiary of Buchang Pharmaceutical, the company focuses on the production of small-volume injections and has made continuous investments in production automation and intelligent quality inspection, enhancing control precision and product inspection efficiency [3] Group 3 - In the "Beautiful Factory" evaluation in Jilin Province, Tonghua Guhong Pharmaceutical was recognized for its outstanding practices in green production, environmental construction, and resource recycling, becoming a model case in the pharmaceutical industry [6] - The company has implemented intelligent upgrades in production, utilizing automated control systems in the traditional Chinese medicine extraction workshop to improve efficiency and reduce energy consumption, while AI visual inspection technology has enhanced product quality detection accuracy in the formulation workshop [6] Group 4 - The company has increased green coverage, built ecological facilities, and upgraded boiler and wastewater treatment systems, which have reduced pollutant emissions and improved resource utilization efficiency [6] - Additionally, the company has constructed cultural activity facilities for employees, enriching their leisure life and promoting the integration of cultural and production environments [6] Group 5 - The company plans to continue adhering to the principles of green development and innovation-driven strategies, further optimizing production processes and increasing R&D investment to enhance its core competitiveness and contribute to regional ecological civilization and high-quality development in the pharmaceutical industry [6]